Daniel M. Bradbury
President and Chief Executive Officer, Amylin Pharmaceuticals  Chief Executive Officer of Amylin Pharmaceuticals since March 2007, serving as President since June 2006 and as Chief Operating Officer since June 2003. Previously served as Senior Vice President of Corporate Development and Vice President of Marketing, having joined Amylin in 1994. Prior to joining Amylin, spent ten years at SmithKline Beecham Pharmaceuticals. A member of the board of directors of Illumina, Inc. and Novacea, Inc.; board member for PhRMA, BIOCOM, and the San Diego Regional Economic Development Corporation.
|
